Eman M Habib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eman M Habib has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Amira M. Ibrahim
Kafrelsheikh University, Kafrelsheikh, Egypt
1 shared publication Asmaa E Hassan
Clinical Pathology, Kafr el-Sheikh University, Kafr el-Sheikh, Egypt
1 shared publicationAtef M Taha
Internal Medicine, Tanta University Faculty of Medicine, Tanta, Egypt
1 shared publicationDalia E Sherief
Clinical Pathology, Kafr el-Sheikh University, Kafr el-Sheikh, Egypt
1 shared publicationEman Sherif
Rheumatology and Rehabilitation department, Kafrelsheikh University, Kafrelsheikh, Egypt
1 shared publicationManal A Eid
Clinical Pathology, Tanta University Faculty of Medicine, Tanta, Egypt
1 shared publication
Latest Publications
- Open Access
- 3 August 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 66
Serum sclerostin level in premenopausal women with rheumatoid arthritis: relation to disease activity, fracture risk and bone mineral density
Background: Rheumatoid arthritis (RA) is associated with increased risk of fractures due to decreased bone mass. Sclerostin is a glycoprotein that suppresses bone formation. It is expressed in osteocytes and some chondrocytes and works by suppressing osteoblast activity. This study aimed to assess the relation between serum sclerostin and rheumatoid disease activity, bone mineral density (BMD) and subsequently fracture risk. Patients and methods: This case-control study included 50 premenopausal RA female (aged 18–50 years), and 50 healthy controls (aged, sex matched). Serum sclerostin level was assessed for all participants. Disease activity score (DAS28), BMD and fracture risk assessment tool (FRAX) were assessed for RA patients. Results: RA patients showed higher levels of serum sclerostin compared to healthy controls, with mean (6.63 ± 4.60 vs. 4.62 ± 2.09 ng/mL, p = 0.047). Serum sclerostin was not correlated with DAS28. There was a negative correlation between serum sclerostin and radius T-score ( r = − 0.298, p = 0.036), and Z-score ( r = -0.278, p = 0.049). No correlations were found between serum sclerostin and femoral neck BMD, lumbar spine (T- and Z-scores), or major osteoporotic or hip fracture scores. DAS28 was negatively correlated with radius T-score ( r = − 0.295, p = 0.038) and radius Z-score ( r = − 0.340, p = 0.016). FRAX scores (major osteoporotic fracture and hip fracture) were positively correlated with age ( r = 0.646 and 0.397, respectively; both p < 0.01) disease duration ( r = 0.480 and 0.426 respectively; both p < 0.01), in addition to the duration of steroid therapy, particularly the duration of the minimum dose ( r = 0.357 and 0.460, p = 0.011 and 0.001 for major osteoporotic and hip fracture, respectively), and with the duration of the maximum dose for hip fracture ( r = 0.300, p = 0.034). Conclusion: Serum sclerostin level is elevated in women with RA compared to healthy controls and is related to reduced peripheral BMD. Progressive disease factors such as longer disease duration, older age and higher disease activity, may contribute to worsening bone health and increased risk of hip and major osteoporotic fractures. Additionally, prolonged corticosteroid therapy may further exacerbate fracture risk. Overall, these findings highlight that BMD declines with advancing RA duration and activity, underscoring the importance of monitoring both disease progression and treatment exposures to mitigate fracture risk. Tight control of disease activity in RA patients is essential, as it may help preserve BMD and reduce the risk of OP. The use of steroids should be carefully limited to the lowest effective dose and shortest possible duration, particularly in patients at high risk of bone loss.
- 3 August 2026
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 53 (1) , 66
Open AccessSerum sclerostin level in premenopausal women with rheumatoid arthritis: relation to disease activity, fracture risk and bone mineral density
Background: Rheumatoid arthritis (RA) is associated with increased risk of fractures due to decreased bone mass. Sclerostin is a glycoprotein that suppresses bone formation. It is expressed in osteocytes and some chondrocytes and works by suppressing osteoblast activity. This study aimed to assess the relation between serum sclerostin and rheumatoid disease activity, bone mineral density (BMD) and subsequently fracture risk. Patients and methods: This case-control study included 50 premenopausal RA female (aged 18–50 years), and 50 healthy controls (aged, sex matched). Serum sclerostin level was assessed for all participants. Disease activity score (DAS28), BMD and fracture risk assessment tool (FRAX) were assessed for RA patients. Results: RA patients showed higher levels of serum sclerostin compared to healthy controls, with mean (6.63 ± 4.60 vs. 4.62 ± 2.09 ng/mL, p = 0.047). Serum sclerostin was not correlated with DAS28. There was a negative correlation between serum sclerostin and radius T-score ( r = − 0.298, p = 0.036), and Z-score ( r = -0.278, p = 0.049). No correlations were found between serum sclerostin and femoral neck BMD, lumbar spine (T- and Z-scores), or major osteoporotic or hip fracture scores. DAS28 was negatively correlated with radius T-score ( r = − 0.295, p = 0.038) and radius Z-score ( r = − 0.340, p = 0.016). FRAX scores (major osteoporotic fracture and hip fracture) were positively correlated with age ( r = 0.646 and 0.397, respectively; both p < 0.01) disease duration ( r = 0.480 and 0.426 respectively; both p < 0.01), in addition to the duration of steroid therapy, particularly the duration of the minimum dose ( r = 0.357 and 0.460, p = 0.011 and 0.001 for major osteoporotic and hip fracture, respectively), and with the duration of the maximum dose for hip fracture ( r = 0.300, p = 0.034). Conclusion: Serum sclerostin level is elevated in women with RA compared to healthy controls and is related to reduced peripheral BMD. Progressive disease factors such as longer disease duration, older age and higher disease activity, may contribute to worsening bone health and increased risk of hip and major osteoporotic fractures. Additionally, prolonged corticosteroid therapy may further exacerbate fracture risk. Overall, these findings highlight that BMD declines with advancing RA duration and activity, underscoring the importance of monitoring both disease progression and treatment exposures to mitigate fracture risk. Tight control of disease activity in RA patients is essential, as it may help preserve BMD and reduce the risk of OP. The use of steroids should be carefully limited to the lowest effective dose and shortest possible duration, particularly in patients at high risk of bone loss.
- 1 February 2021
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (2) , 333-337
Circulating Mir-146A Expression Predicts Early Treatment Response to Imatinib in Adult Chronic Myeloid Leukemia
This study aimed to investigate the prognostic role of circulating miR-146a in the prediction of early response to imatinib treatment in patients with chronic myeloid leukemia (CML). Sixty patients with CML and 20 healthy controls were recruited in this study. BCR-ABL was assessed by quantitative rt-PCR at days 0 and 90 of imatinib therapy. Circulating miR-146a levels were assessed by quantitative rt-PCR at days 0, 14 and 90 of imatinib therapy for patients and once for controls. At day 90 of treatment, treatment response was achieved in 48 patients (80.0%). Responders had significantly lower baseline Sokal score when compared with non-responders. They also had significantly lower BCR-ABL expression at day 90 of treatment. The circulating miR-146a level was significantly lower in patients with CML than in healthy subjects and showed a significant rise after 14 days of imatinib treatment and an inverse correlation with BCR-ABL expression levels at 90 days. Using multivariate logistic regression analysis, baseline BCR-ABL (%) (OR (95% CI) 1.09 (1.03 to 1.016), p=0.006) and miR-146a at 14 days (OR (95% CI) 0.002 (0.0 to 0.09), p=0.001) were significant predictors of treatment response. Using ROC curve analysis, it was found that miR-146a expression at 14 and 90 days could distinguish responders from non-responders (AUC (95% CI) 0.849 (0.733 to 0.928) and 0.867 (0.755 to 0.941), respectively). This study reported for the first time that measurement of the circulating miR-146a expression at 14 days can predict the early response to imatinib treatment in patients with CML. Thus, this work indicates that miR-146a should be investigated in the setting of treatment response to other tyrosine kinase inhibitors.
- 1 February 2021
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (2) , 333-337
Circulating Mir-146A Expression Predicts Early Treatment Response to Imatinib in Adult Chronic Myeloid Leukemia
This study aimed to investigate the prognostic role of circulating miR-146a in the prediction of early response to imatinib treatment in patients with chronic myeloid leukemia (CML). Sixty patients with CML and 20 healthy controls were recruited in this study. BCR-ABL was assessed by quantitative rt-PCR at days 0 and 90 of imatinib therapy. Circulating miR-146a levels were assessed by quantitative rt-PCR at days 0, 14 and 90 of imatinib therapy for patients and once for controls. At day 90 of treatment, treatment response was achieved in 48 patients (80.0%). Responders had significantly lower baseline Sokal score when compared with non-responders. They also had significantly lower BCR-ABL expression at day 90 of treatment. The circulating miR-146a level was significantly lower in patients with CML than in healthy subjects and showed a significant rise after 14 days of imatinib treatment and an inverse correlation with BCR-ABL expression levels at 90 days. Using multivariate logistic regression analysis, baseline BCR-ABL (%) (OR (95% CI) 1.09 (1.03 to 1.016), p=0.006) and miR-146a at 14 days (OR (95% CI) 0.002 (0.0 to 0.09), p=0.001) were significant predictors of treatment response. Using ROC curve analysis, it was found that miR-146a expression at 14 and 90 days could distinguish responders from non-responders (AUC (95% CI) 0.849 (0.733 to 0.928) and 0.867 (0.755 to 0.941), respectively). This study reported for the first time that measurement of the circulating miR-146a expression at 14 days can predict the early response to imatinib treatment in patients with CML. Thus, this work indicates that miR-146a should be investigated in the setting of treatment response to other tyrosine kinase inhibitors.